Evidence map›Paper›PMID 35779106›Full record

ArticleJournal of cancer research and clinical oncology2023

Predicting time to treatment in follicular lymphoma on watchful waiting using baseline metabolic tumour burden.

Lucia Leccisotti, Daria Maccora, Rosalia Malafronte, Francesco D'Alò, Elena Maiolo, Salvatore Annunziata, Vittoria Rufini, Alessandro Giordano, Stefan Hohaus

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. The Predictive Role of BaselineDiagnostics (Basel, Switzerland) · 2025
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lucia LeccisottiUnit of Nuclear Medicine, Department of Diagnostic Imaging, Radiation Oncology and Haematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo A. Gemelli, 8, 00168, Rome, Italy. lucia.leccisotti@policlinicogemelli.it.ORCID http://orcid.org/0000-0002-6000-2898
Daria MaccoraUniversity Department of Radiological Sciences and Haematology, Università Cattolica del Sacro Cuore, Rome, Italy.
Rosalia MalafronteUniversity Department of Radiological Sciences and Haematology, Università Cattolica del Sacro Cuore, Rome, Italy.
Francesco D'AlòUniversity Department of Radiological Sciences and Haematology, Università Cattolica del Sacro Cuore, Rome, Italy.
Elena MaioloUnit of Extramedullary Lymphoproliferative Diseases, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Salvatore AnnunziataUnit of Nuclear Medicine, Department of Diagnostic Imaging, Radiation Oncology and Haematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo A. Gemelli, 8, 00168, Rome, Italy.
Vittoria RufiniUnit of Nuclear Medicine, Department of Diagnostic Imaging, Radiation Oncology and Haematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo A. Gemelli, 8, 00168, Rome, Italy.
Alessandro GiordanoUnit of Nuclear Medicine, Department of Diagnostic Imaging, Radiation Oncology and Haematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo A. Gemelli, 8, 00168, Rome, Italy.
Stefan HohausUniversity Department of Radiological Sciences and Haematology, Università Cattolica del Sacro Cuore, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAsymptomatic patients with follicular lymphoma (FL) and a low tumour burden can be followed without initial therapy, a strategy called watchful waiting (WW). Prediction of the time to treatment (TTT) is still a challenge. We investigated the prognostic value of baseline total metabolic tumour volume (TMTV) and whole-body total lesion glycolysis (WB-TLG) to predict TTT in patients with FL on WW.

methodsWe conducted a retrospective study of 54 patients with FL (grade 1-3a) diagnosed between June 2013 and December 2019, staged with FDG PET/CT, and managed on WW. Median age was 62 years (range 34-85), stage was advanced (III-IV) in 57%, and FLIPI score was intermediate to high (≥ 2) in 52% of the patients.

resultsThe median TMTV and WB-TLG were 7.1 and 43.3, respectively. With a median follow-up of 59 months, 41% of patients started immuno-chemotherapy. The optimal cut-points to identify patients with TTT within 24 months were 14 for TMTV (AUC 0.70; 95% CI 51-88) and 64 for WB-TLG (AUC 0.71; 95% CI 52-89) (p < 0.005). The probability of not having started treatment within 24 months was 87% for TMTV < 14 and 53% for TMTV ≥ 14 (p < 0.005). TMTV was independent of the FLIPI score for TTT prediction. Patients with both FLIPI ≥ 2 and TMTV ≥ 14 had only an 18% probability of not having started treatment at 36 months, while this probability was 75% in patients with TMTV < 14.

conclusionMetabolic tumour volume parameters may add information to clinical scores to better predict TTT and better stratify patients for interventional studies.

Indexed as

Lymphoma, FollicularPositron Emission Tomography Computed TomographyAdultAgedAged, 80 and overFluorodeoxyglucose F18HumansMiddle AgedPrognosisRetrospective StudiesTime-to-TreatmentTumor BurdenWatchful WaitingFluorodeoxyglucose F18FDGFollicular lymphomaMetabolic tumour volumePETPET/CTWatchful waiting

Identifiers

PMID35779106
PMCPMC10314847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.